SCHEMBL4013430

SCHEMBL4013430

Cc1n[nH]c2ccc(S(=O)(=O)Nc3ccc(Cl)c(Cl)c3)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 1/20 0.53
PKM P14618 2/20 0.51
MAPT P10636 3/20 0.49
LMNA P02545 2/20 0.49
TP53 P04637 1/20 0.49
KIT P10721 1/20 0.49
PKLR P30613 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
HTR6 P50406 1/20 0.47
NAPEPLD Q6IQ20 1/20 0.46
EDNRB P24530 1/20 0.45
EDNRA P25101 1/20 0.45
PSEN1 P49768 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1460607 0.95 KIT (0.52) MAP2K4PKMMAPTLMNAKIT
SCHEMBL4007929 0.88 MAP2K4 (0.54) MAP2K4PKMMAPTLMNATP53
SCHEMBL4007831 0.85 MAP2K4 (0.55) MAP2K4PKMMAPTLMNATP53
SCHEMBL4006853 0.85 MAP2K4 (0.53) MAP2K4PKMMAPTLMNATP53
SCHEMBL1461661 0.82 MAP2K4 (0.52) MAP2K4PKMMAPTLMNAKIT
SCHEMBL3303810 0.82 CYP3A4 (0.54) MAPTCYP3A4CYP2D6HTR6PSEN1
SCHEMBL4009760 0.82 MAP2K4 (0.63) MAP2K4MAPTTP53KITLNPEP
SCHEMBL4014398 0.82 MAP2K4 (0.50) MAP2K4PKMMAPTLMNATP53
SCHEMBL4005840 0.82 MAP2K4 (0.48) MAP2K4PKMMAPTLMNATP53
SCHEMBL27676127 0.81 JAK2 (0.54) MAP2K4PKMMAPTLMNAKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 MAP2K4 340/4885PKM 621/4885MAPT 2426/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 MAP2K4 328/4885PKM 748/4885MAPT 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.